These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 28017775)
1. The network of immunosuppressive pathways in glioblastoma. Mangani D; Weller M; Roth P Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775 [TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive mechanisms in glioblastoma. Nduom EK; Weller M; Heimberger AB Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii9-vii14. PubMed ID: 26516226 [TBL] [Abstract][Full Text] [Related]
3. Glioblastoma-derived mechanisms of systemic immunosuppression. Waziri A Neurosurg Clin N Am; 2010 Jan; 21(1):31-42. PubMed ID: 19944964 [TBL] [Abstract][Full Text] [Related]
4. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment. Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB Front Immunol; 2020; 11():582106. PubMed ID: 33178210 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development. Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B Cells; 2021 Jan; 10(2):. PubMed ID: 33572835 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for the treatment of glioblastoma. Thomas AA; Ernstoff MS; Fadul CE Cancer J; 2012; 18(1):59-68. PubMed ID: 22290259 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for glioma: promises and challenges. Han SJ; Zygourakis C; Lim M; Parsa AT Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649 [TBL] [Abstract][Full Text] [Related]
8. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. Mirzaei R; Sarkar S; Yong VW Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820 [TBL] [Abstract][Full Text] [Related]
9. Advances in Immunotherapy for Glioblastoma Multiforme. Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for Glioblastoma: Current Progress and Challenges. Yu MW; Quail DF Front Immunol; 2021; 12():676301. PubMed ID: 34054867 [TBL] [Abstract][Full Text] [Related]
11. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives. Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171 [TBL] [Abstract][Full Text] [Related]
12. Advances in immunotherapy for the treatment of glioblastoma. Tivnan A; Heilinger T; Lavelle EC; Prehn JH J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144 [TBL] [Abstract][Full Text] [Related]
14. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Pombo Antunes AR; Scheyltjens I; Duerinck J; Neyns B; Movahedi K; Van Ginderachter JA Elife; 2020 Feb; 9():. PubMed ID: 32014107 [TBL] [Abstract][Full Text] [Related]
15. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma. Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698 [TBL] [Abstract][Full Text] [Related]
16. Current Advances in Immunotherapy for Glioblastoma. Mende AL; Schulte JD; Okada H; Clarke JL Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Neuro-Oncology. Majd N; Dasgupta P; de Groot J Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015 [TBL] [Abstract][Full Text] [Related]